Plasma Gelsolin is a key component of the innate immune system – the first line of defense against threats to the body. This innate system is not pathogen-specific and reacts equally well to a wide variety of organisms.
Key Component of Innate Immunity Read More »
Plasma gelsolin’s unique role is to modulate the necessary inflammatory response so that what was intended to be a mechanism of healing does not become an instrument of morbidity and death.
Regulates Inflammation Read More »
Fast Track status accelerates regulatory pathway for BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. Second Fast Track designation in recent months highlights broad potential of rhu-pGSN across multiple diverse inflammation-driven conditions. NORTH BRUNSWICK, N.J., August 20, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of
Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. Global Phase 2b clinical trial underway evaluating rhu-pGSN for the treatment of moderate to severe ARDS. NORTH BRUNSWICK, N.J., June 17, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech
Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of inflammatory diseases, to be studied as an intervention for the negative outcomes of decompression in SCUBA Divers. NORTH BRUNSWICK, N.J., June 10, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for acute and chronic inflammatory
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study expected to inform therapeutic strategies beyond ARDS, positioning rhu-pGSN as a promising intervention across a spectrum of acute and chronic inflammatory diseases. NORTH BRUNSWICK, N.J., May 6, 2025
Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025. COO Valerie Ceva will present at MedInvest Biotech & Pharma Investor Conference in NYC on March 27, 2025. NORTH BRUNSWICK, N.J., March 18, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics,
BioAegis COO and Co-founder, Valerie Ceva, was invited to present at the upcoming MedInvest Biotech & Pharma Investor Conference in New York City. The presentation, “Conquering Disease Driven by Excess Inflammation” will highlight BioAegis’ novel, host-directed immune regulator protein. The presentation will also discuss BioAegis’ lead indication, Acute Respiratory Distress Syndrome (ARDS), and its phase
March 27-28, 2025: MedInvest Biotech & Pharma Investor Conference Read More »
BioAegis is a sponsor of the upcoming International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium from March 18-21, 2025. Current information on our ongoing ARDS trial will be presented at this key critical care conference.
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Endogenous levels plummet in ARDS, correlating with disease severity. NORTH BRUNSWICK, N.J., October 17, 2024 (GLOBE NEWSWIRE) — BioAegis Therapeutics,